ClinicalTrials.gg
RecruitingNCT05947149HadroQoLUpdated Aug 6, 2025

HRQoL in Patients With Solid Tumors Treated With Hadrontherapy

An observational study in Head and Neck Cancer, Skull Base--Cancer and Brain Cancer, sponsored by CNAO National Center of Oncological Hadrontherapy. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-06.

Sponsored by CNAO National Center of Oncological Hadrontherapy · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
180
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 134 studies in Head and Neck Neoplasms with a site in Italy — 42 open to participants now, 56 under way, 6 of them phase 3. Head and Neck Neoplasms · Italy.

Planned enrollment
20th of 37
180 · median 200
Started
2023
with 13 others
Observational
37 of 134
24 open now
Primary completion
2025-09
later than 11 of 55 live
Registered
91st of 134
by date
Lead sponsor
3 of 134
CNAO National Center of Oncological Hadrontherapy

Among the 134 studies in Head and Neck Neoplasms with a site in Italy, this one is the 20th largest by planned enrollment of the 37 observational ones that give a count, is one of 14 that started in 2023, is one of 37 observational ones, reaches primary completion later than 11 of the 55 other live ones, and was the 91st registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

42 of the 134 studies in Head and Neck Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Head and Neck Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

The Quality of Life of patients treated with hadrontherapy is still limited. Two cohorts are established, they will be receiving specific standardized questionnaires to be evalutaed in their results.

Read the detailed description

Since 2011, CNAO has been treating patients suffering from solid tumors with particle therapy (both protons and carbon ions). Hadrontherapy improves outcome of radioresistant tumors which normally do not benefit from conventional radiotherapy. The treated population is highly heterogenous in term of tumor site, histotype, treatment fields and doses however its common anatomical origin justifies a unified approach in evaluating a QoL in this setting. QoL of patients suffering from these tumors have been poorly investigated and there are still few studies on patient reported outcomes (PROs) and QoL following hadrontherapy. In this context, therefore, there is a need to generate data by designing distinct cohort studies, conceived within a single protocol, that will gather quality of life data by means of standardized questionnaires of patients along their oncological history. Thanks to this protocol design, the investigator will be facilitated, in the future, in adding new cohorts pending a study protocol amendment and ethical approval.

03

Conditions studied

  • Head and Neck Cancer
  • Skull Base--Cancer
  • Brain Cancer

Keywords

  • cancer free survisorship
  • hadrontherapy
  • quality of life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The patients from cohort A will be selected and invited to participate in the study when evaluated for standard of care follow-up which is taking place in telemedicine modality through a digital meeting organized by the staff.

Patients from Cohort B with indication of hadrontherapy in radical setting will be consecutively enrolled at baseline (during CT simulation procedure or at the first session of RT).

Eligibility criteria

Cohort A ("survivors"):

Inclusion Criteria

  • Patients with at least a follow up of 5 years with head and neck, skull base and brain tumors and no evidence of progressive disease.
  • The patient is able to give consent

Exclusion Criteria:

  • Re-irradiation.
  • Second tumor.
  • Known cases of any psychiatric and neurological diseases leading to disability (eg, manic disorder, schizophrenia etc..), which could impair compilation of questionnaires or affect quality of life.

Cohort B:

Inclusion Criteria:

  • Histological and/or radiological diagnosis of head and neck tumors
  • Patients candidate for curative intent hadrontherapy
  • Patients ≥ 18 years of age
  • The patient is able to give consent

Exclusion criteria:

  • Re-irradiation.
  • Second tumor
  • Known cases of any psychiatric and neurological diseases leading to disability (eg, manic disorder, schizophrenia etc..), which could impair compilation of questionnaires or affect quality of life
  • Presence of diffused
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
180 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort A Survivors

    about 80 patients with at least a 5 year follow up with head and neck, skull base and brain tumors and no evidence of progressive disease.

    Other: questionnaires administration

  • Cohort B

    100 patients with histological and/or radiological diagnosis of head and neck tumors enrolled at baseline

    Other: questionnaires administration

Interventions

  • Otherquestionnaires administration

    Enrolled people will be requested to fill in questionnaires. Cohort A affected by head and neck cancer: SF-12, EORTC QLQ-C30, EORTC QLQ-H\&N43, HADS, Brief COPE, BRCS. Cohort A affected by skull base/brain cancer: SF-12, EORTC QLQ-BN20, HADS, Brief COPE, BRCS. Cohort B will receive: EORTC QLQ-C30, BRCS, PROFFIT, SF-12, EORTC QLQ-H\&N43.

06

What researchers measure

Primary outcomes

  1. investigate relation between quality of life and several socio- psycho- variables

    quality of life in subjects treated with curative hadrontherapy investigated by global score according to Short-form-12-health-survey-questionnaire (SF-12) and compared to healthy population

    Time frame: 5 years follow uo after hadrontherapy

Secondary outcomes

  1. quality of life related also to psychological variables, socio-cognitive factors, resilience

    quality of life in subjects treated with curative hadrontherapy investigated by global score according to EORTC QLQ-C30

    Time frame: before treatment and after 1 year from treatment completion

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Sep 2025, 29 months after the start.

Of 216 non-industry observational studies under Head and Neck Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 144. This study's planned 29 months is below that.

Counting every sponsor, half of 238 studies reached it within 69 months; a quarter within 29 and three quarters within 144.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2023
First posted
Jul 17, 2023
StartActual
Mar 27, 2023
Primary completionEst.
Sep 26, 2025
CompletionEst.
Sep 26, 2025
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05947149
Lead sponsor
CNAO National Center of Oncological Hadrontherapy
Responsible party
Sponsor
First posted
Jul 17, 2023
Start date
Mar 27, 2023
Primary completion
Sep 26, 2025 (estimated)
Completion
Sep 26, 2025 (estimated)
Last update
Aug 6, 2025

Study contacts

Anna Maria Camarda
Contact
camarda@cnao.it
+390382078501
Cristina Bono
Contact
bono@cnao.it
+390382078613
Anna Maria Camarda
principal investigator · CNAO National Center of Oncological Hadrontherapy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion